Interferon News and Research

RSS

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

Key molecule helps identify renal cell carcinoma

Mayo Clinic researchers have discovered a key molecule that lets doctors identify one of the most aggressive types of kidney cancer. Patients with renal cell carcinoma who have higher levels of a molecule known as B7-H1 in their tumors are nearly five times more likely to die from the disease than patients with low levels or an absence of the molecule.

30 Nov 2004

MedImmune and Medarex have announced a collaboration to develop antibodies

MedImmune and Medarex have announced a collaboration to develop antibodies targeting interferon-alpha and the type I interferon receptor 1.

24 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Eisai In-licenses Anti-hepatitis B Agent clevudine From Bukwang Pharm

Eisai Co., Ltd. announced today that the Company has in-licensed an anti-hepatitis B agent (generic name: clevudine) from Bukwang Pharm (Headquarters, Seoul, South Korea, President: Sung-Koo Lee).

16 Nov 2004

Cellular vehicle delivers drugs directly into cancer cells

Researchers at The University of Texas M. D. Anderson Cancer Center have perfected a delivery system for anticancer treatment that zeroes in on a tumor and becomes part of its supporting tissue.

4 Nov 2004

New approaches for the treatment of chronic hepatitis C

Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C was presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

1 Nov 2004

Discovery of a number of potent and selective small molecule inhibitors of the hepatitis C (HCV) NS3/4 protease

InterMune announced today the presentation of preclinical data on the discovery and characterization of a number of potent and selective small molecule inhibitors of the hepatitis C (HCV) NS3/4 protease.

1 Nov 2004

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Interim study results indicate a certain drug combination treatment may suppress the hepatitis C virus more quickly than another.

1 Nov 2004

Scientists have uncovered a significant new link in the chain of immune system events through which estrogen prevents bone loss

Through research in mice, the scientists discovered that an immune signaling molecule called type b transforming growth factor (TGFb) is responsible for a cascade of events that leads estrogen to prevent bone loss.

29 Oct 2004

New understanding of how poxviruses jump from species to species

A Canadian study conducted at Robarts Research Institute sheds new light on how poxviruses can jump from species to species -- and will lead to further exploration of another potential candidate in the emerging field of “oncolytic viruses” to fight cancer.

25 Oct 2004

Evidence showing treatment benefits of beta interferon for multiple sclerosis

Results of a European study in this week’s issue of THE LANCET provide further evidence that patients with early symptoms of multiple sclerosis given a weekly injection with interferon beta are less likely to progress to full clinical disease after two years follow-up.

21 Oct 2004

Dermatologists now have many treatment options that can significantly reduce the appearance of scars or make them disappear all together

The scar you received when you fell off your bike at age 12 or from a recent car accident may be a constant and painful reminder of the event. While you may not feel any physical pain from these wounds, scars can make you feel self-conscious or embarrassed, particularly if they are located on exposed skin.

13 Oct 2004

Signaling pathway could be a valuable target for future drug therapies against systemic lupus erythematosus

Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in “Nature Immunology.”

11 Oct 2004

Significant progress in development of an animal model of smallpox that closely resembles human disease

Scientists have made significant progress in developing an animal model of smallpox that closely resembles human disease, which will be necessary for testing of future vaccines and potential treatments.

5 Oct 2004

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Ribavirin Capsules, 200 mg. Shipment of this product is expected to begin immediately.

5 Oct 2004

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease

A trial of beta-interferon-1a in inclusion-body myositis (IBM) has failed to find benefit from the drug in this disease. Beta-interferons counteract some of the activities of the immune system, which some experts believe is misguided in IBM.

5 Oct 2004

Researchers discover new mechanism responsible for blood vessel tumors that cause facial deformities

Researchers have discovered a new mechanism responsible for the growth of blood vessel tumors that can cause facial deformities in infants and young children, paving the way for an antibody-based treatment to remove cells that fuel the tumors’ growth.

5 Oct 2004

Cancer vaccine based on listeria bacteria shows promise

An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

29 Sep 2004

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

Interferon News and Research

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Key molecule helps identify renal cell carcinoma

MedImmune and Medarex have announced a collaboration to develop antibodies

FDA approval of Tysabri, for the treatment of multiple sclerosis

Eisai In-licenses Anti-hepatitis B Agent clevudine From Bukwang Pharm

Cellular vehicle delivers drugs directly into cancer cells

New approaches for the treatment of chronic hepatitis C

Discovery of a number of potent and selective small molecule inhibitors of the hepatitis C (HCV) NS3/4 protease

Pegasys with ribavirin combo may best for reducing hepatitis C viral levels

Scientists have uncovered a significant new link in the chain of immune system events through which estrogen prevents bone loss

New understanding of how poxviruses jump from species to species

Evidence showing treatment benefits of beta interferon for multiple sclerosis

Dermatologists now have many treatment options that can significantly reduce the appearance of scars or make them disappear all together

Signaling pathway could be a valuable target for future drug therapies against systemic lupus erythematosus

Significant progress in development of an animal model of smallpox that closely resembles human disease

Teva Pharmaceuticals granted final approval for Ribavirin capsules

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease

Researchers discover new mechanism responsible for blood vessel tumors that cause facial deformities

Cancer vaccine based on listeria bacteria shows promise

New anti-inflammatory strategy for cancer therapy

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News